Sakran W, Raz R, Colodner R, Keness Y
Infectious Disease Unit, HaEemek Medical Center, Afula.
Harefuah. 1997 Nov 2;133(9):365-6, 414.
Erythromycin is considered the drug of choice in the treatment of streptococcal pharyngitis in patients allergic to penicillin. However, in recent years several publications, especially in Finland and Italy, showed high resistance rates of S. pyogenes isolates to erythromycin and other new macrolides. To evaluate the situation in Israel, we checked the MIC of isolates from patients with tonsillitis during 1996. E-test results showed an MIC-50 of 0.23, 0.13 and 0.47 mcg/ml for erythromycin, clarithromycin and roxithromycin, respectively and a MIC-90 of 0.37, 0.23 and 0.78 mcg/ml. Only 2 isolates (2.1%) were partially or completely resistant to all 3 antibiotics. We conclude that empiric therapy with macrolides in Israel is still a viable option and can be recommended in S. pyogenes tonsillitis for patients allergic to penicillin.
对于对青霉素过敏的患者，红霉素被认为是治疗链球菌性咽炎的首选药物。然而，近年来，一些出版物，特别是在芬兰和意大利的，显示化脓性链球菌分离株对红霉素和其他新型大环内酯类药物的耐药率很高。为了评估以色列的情况，我们检查了1996年期间扁桃体炎患者分离株的最低抑菌浓度（MIC）。E试验结果显示，红霉素、克拉霉素和罗红霉素的MIC50分别为0.23、0.13和0.47微克/毫升，MIC90分别为0.37、0.23和0.78微克/毫升。只有2株分离株（2.1%）对所有3种抗生素部分或完全耐药。我们得出结论，在以色列，大环内酯类药物的经验性治疗仍然是一个可行的选择，对于对青霉素过敏的化脓性链球菌扁桃体炎患者可以推荐使用。
